Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors
Journal of the National Comprehensive Cancer Network · 2024
DOI: 10.6004/jnccn.2023.7116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Fadi G Haddad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-moderate, or even severe but reversible, adverse events may be preferable to switching to a different TKI. The selection of second-line and beyond therapies depends on the evolving patterns observed with frontline treatment. Dose-adjusted ponatinib schedules have demonstrated improved efficacy and safety in patients resistant to second-generation TKIs or those with T315I-mutated disease. For asciminib, longer-term follow-up is needed to better evaluate its safety and efficacy compared with ponatinib. Allogeneic stem cell transplantation represents a valid alternative to newer-generation TKIs, with a better treatment value when TKIs are priced at >$40,000/year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zitieren
APA
Haddad, F. G., & Kantarjian, H. (2024). Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.7116
Vancouver
Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2023.7116
BibTeX
@article{Haddad2024,
author = {Haddad, Fadi G and Kantarjian, Hagop},
title = {Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
doi = {10.6004/jnccn.2023.7116}
}
EUVIMED